LATIN AMERICA
Optimal quality control in the manufacture of medicines
( a total of USD $ 18 million over the last four years ), in which more than 4,000 patients have benefited from these programs . In the near future , its portfolio will incorporate products for the treatment of diabetes , which is a high prevalence disease in the country .
“ We are working on activities to develop and promote our scientific leadership by bringing AstraZeneca products to more and more patients and by developing medical education programs for health professionals in Mexico ,” said the ceo of AstraZeneca Mexico .
“ We have high standards , therefore we only work with suppliers who are equivalent to our own ethical values ”
– Ugo de Jacobis , CEO of AstraZeneca Mexico
www . astrazeneca . com / mexico 121